- Faron Pharmaceuticals said it planned to recruit extra patients into its cancer trial after a data monitoring committee confirmed the safe dose range of the trial.

The company received confirmation that its cancer drug, Clevegen, had achieved 'good' tolerability in the trial across all dosing levels -- in a range of 0.3 to 10 mg per kg of Clevegen -- with no dose limiting toxicity observed. The company would adopt the data monitoring committee's advice and had decided to 'expand Part I to approximately 30 patients in total to determine optimal dosing before moving to Part II,' Faron said. A maximally tolerated dose of the had not been reached, but the company said it believed that it could quickly obtain additional data to select the optimal dose for expansion cohorts.

'Now that a safe dose range has been confirmed, Faron believe that the remaining patients for the trial can be recruited relatively quickly,' it added. At 9:57am: [LON:FARN] Faron Pharmaceuticals share price was +5.5p at 86p

Story provided by